Global X MSCI Argentina ETF vs Crispr Therapeutics AG — how do they compare? Global X MSCI Argentina ETF trades at $91.95, while Crispr Therapeutics AG trades at $53.86 (market cap $5.23B). The key difference: Global X MSCI Argentina ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| ARGT | CRSP | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $102.94 | $76.78 |
52-Week Low | $67.55 | $44.34 |
Market Cap | — | $5.23B |
Enterprise Value | — | $3.65B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Trailing returns across standard periods
ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.
Read more on ARGT →CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →